Cantor Fitzgerald initiates coverage of Ensysce Biosciences with Overweight rating, $2 price target
Cantor Fitzgerald initiated coverage of Ensysce Biosciences with an Overweight rating and a $2.00 price target, implying a 297.7% upside from the Oct 19 close of $0.50. The analyst highlights the company's potential in treating chronic pain with its CY200 formulation, citing strong clinical rationale and promising early data.
How this was made
The 30-second read
Why it matters
The coverage could spark short‑term buying and increase volatility in the micro‑cap biotech space.
Market read
New coverage on a micro‑cap biotech may create short‑term price movement but limited broader market effect.
What to watch
Regulatory timeline and competitive pipeline could temper upside.
Background
Analyst note introducing Ensysce Biosciences to investors with a high price target.
Market effects
Potential boost to other psychedelic‑based biotech stocks as coverage highlights the sector.
Limited to U.S. biotech market participants.
Minimal global impact beyond niche biotech investors.
Counterpoint
Target may be overly optimistic given early‑stage data; price could be volatile.
Key entities
- AnalystCantor Fitzgerald
Investment bank providing the coverage.
- CompanyEnsysce Biosciences
Biotech firm developing psilocybin‑based therapy CY200.
